Topics

Glioblastoma | Treatment | Clinical trials | Margins

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Margins

Tang PLY, Romero AM, Nout RA, van Rij C, Slagter C, Swaak-Kragten AT, Smits M, Warnert EAH.
Amide proton transfer-weighted CEST MRI for radiotherapy target delineation of glioblastoma: a prospective pilot study.
Eur Radiol Exp. 2024 Oct 30;8(1):123. doi: 10.1186/s41747-024-00523-4. PMID: 39477835. Interventional study. ˍ

Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T, Wiehle R, Mader I, Würtemberger U, Langen KJ, Niyazi M, Paulsen F, König L, Giordano FA, Spehl I, Bernhardt D, Schymalla MM, Pöttgen C, Semrau S, Brunner T, Hültenschmidt B, Krause BJ, Ciernik IF, Beck J, Baumert BG, Meyer PT, Urbach H, Popp I; GLIAA Study Group.
O-(2-[¹⁸F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
Lancet Oncol. 2025 Dec 19:S1470-2045(25)00642-4. doi: 10.1016/S1470-2045(25)00642-4. PMID: 41429128. Interventional study. ˍ

Detsky JS, Chan AW, Moore-Palhares D, Safavi AH, Perry J, Fat MJL, Atenafu EG, Das S, Lipsman N, Heyn C, Maralani P, Czarnota GJ, Ruschin M, Keller B, Lau A, Chen H, Myrehaug SD, Soliman H, Tseng CL, Sahgal A.
MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial.
Lancet Oncol. 2026 May 14;27(6):729-737. doi: 10.1016/S1470-2045(26)00088-4. PMID: 42134380. Trial registration ID: NCT04726397˰ ˍ

Ghosh S, Stewart J, Ruschin M, Chen H, Tseng CL, Soliman H, Sahgal A, Detsky J.
Influence of FLAIR inclusion on patterns-of-failure and outcomes in glioblastoma: results from the UNITED prospective adaptive radiotherapy trial.
Radiother Oncol. 2026 May 15;220:111579. doi: 10.1016/j.radonc.2026.111579. PMID: 42142536. Trial registration ID: NCT04726397. ˍ